FB418
- Generic Name
- FB418
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Phase 1
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease Psychosis
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05995782
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath